HK Stock Market Move | XTALPI (02228) rises by over 4% again, ReviR's innovative drug RTX-117 obtains clinical approval in China and the United States.

XTALPI (02228) continues to rise by more than 4%, with a cumulative increase of nearly 50% within the month. As of the time of writing, it has risen by 4.68% to 14.08 Hong Kong dollars, with a turnover of 6.65 billion Hong Kong dollars. On the news front, Crystal Technology announced that its incubated enterprise ReviR Xili Technology's innovative drug pipeline RTX-117 has recently achieved a milestone achievement of "double submission and approval" (IND approval) in China and the United States. In conjunction with several successful collaborations, Crystal Technology will receive a milestone payment totaling tens of millions of Hong Kong dollars from ReviR. ReviR will continue to complete the follow-up clinical development of RTX-117, and Crystal Technology has the right to participate in the sales sharing and subsequent licensing revenue sharing of this pipeline. Guolian Minsheng Securities released a research report stating that XTALPI has formed a moat in the field of AI pharmaceuticals with its hardware and software technology accumulation, platform business model, and key competitive position. The bank believes that the clinical approval of RTX-117 marks the value realization period for its technology platform. With the continuous expansion of the collaborative pipeline fleet, there is a wide space for performance elasticity and valuation reshaping.